KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) EBT (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of EBT data on record, last reported at -$35.0 million in Q3 2025.

  • For Q3 2025, EBT rose 5.47% year-over-year to -$35.0 million; the TTM value through Sep 2025 reached -$113.8 million, up 31.89%, while the annual FY2024 figure was -$119.2 million, 56.65% up from the prior year.
  • EBT reached -$35.0 million in Q3 2025 per NKTR's latest filing, up from -$39.4 million in the prior quarter.
  • Across five years, EBT topped out at $7.0 million in Q4 2024 and bottomed at -$159.0 million in Q2 2022.
  • Average EBT over 5 years is -$74.3 million, with a median of -$52.3 million recorded in 2024.
  • Peak YoY movement for EBT: crashed 56.73% in 2021, then skyrocketed 117.14% in 2024.
  • A 5-year view of EBT shows it stood at -$146.8 million in 2021, then surged by 56.77% to -$63.5 million in 2022, then soared by 35.63% to -$40.8 million in 2023, then surged by 117.14% to $7.0 million in 2024, then plummeted by 600.16% to -$35.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$35.0 million in Q3 2025, -$39.4 million in Q2 2025, and -$46.4 million in Q1 2025.